Can adequate and well controlled trials be designed to study glaucoma neuroprotection? 7 Transl Vis Sci Technol. 2023;12(11):33; Transl Vis Sci Technol. 2025;14(7):11 Study design permits valid comparison Comparator arms should have similar dosing schedules and evaluation timepoints Minimize bias on part of subjects, observers and analysts Randomization and masking of treatment arms Method of assessment is well defined and reliable Endpoints which are important to subjects FDA guidelines for an adequate and well controlled trial: